Marc Martinell
Co-Founder & Chief Executive Officer at Minoryx
Meet Marc Martinell
Marc co-founded Minoryx to provide therapeutic options to patients of orphan diseases with no alternatives. The company recently presented results from its phase II/III ADVANCE study, showing that leriglitazone reduced progression of cerebral lesions and myelopathy symptoms in adrenomyeloneuropathy patients. Martinell has previously worked for Crystax Pharmaceuticals and Oryzon Genomics, where he managed several research projects and led the team in charge of target selection, structural biology, computational chemistry, and hit ID through a fragment-based approach. According to Martinell, the biggest challenge the industry faces this year is uncertainty.